Canopus BioPharma, Inc. Strengthens Its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement with Wisconsin Alumni Research Foundation (WARF)

Published: Jun 18, 2008

LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, today announced the signing of a licensing agreement with the Wisconsin Alumni Research Foundation (WARF), an organization serving the University of Wisconsin-Madison scientific community by patenting the discoveries of UW-Madison researchers and licensing these technologies to leading companies in Wisconsin, the United States and worldwide. The agreement provides comprehensive licensing rights and patent protection relating to Canopus’ Phase II oncology drug candidate, CB1400.

Back to news